Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7138390 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Nov, 2022
(6 months ago) | |
USRE48286 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2027
(3 years from now) | |
US10174073 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8058267 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2022
(1 year, 3 months ago) | |
US8377916 | INTERCEPT PHARMS INC | Steroids as agonists for FXR |
Feb, 2022
(1 year, 3 months ago) | |
US9238673 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Jun, 2033
(10 years from now) | |
US10047117 | INTERCEPT PHARMS INC | Preparation and uses of obeticholic acid |
Sep, 2033
(10 years from now) | |
US10758549 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(12 years from now) | |
US10751349 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(12 years from now) | |
US10052337 | INTERCEPT PHARMS INC | Compositions of obeticholic acid and methods of use |
Apr, 2036
(12 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | May 27, 2023 |
Market Authorisation Date: 27 May, 2016
Treatment: Treatment of primary biliary cholangitis (pbc); Treatment of primary biliary cholangitis (pbc) in combination with ursodeoxycholic acid (udca) in adults with an inadequate response to udca, or as mono...
Dosage: TABLET;ORAL
33
United States
11
Japan
9
Australia
9
European Union
6
Israel
6
Korea, Republic of
6
Canada
6
Singapore
4
EA
4
Chile
4
Mexico
4
Brazil
4
China
3
Colombia
3
New Zealand
3
Philippines
2
Denmark
2
Spain
2
Morocco
2
Norway
2
Taiwan
1
Ecuador
1
India
1
El Salvador
1
Netherlands
1
Tunisia
1
Peru
1
Costa Rica
1
Austria
1
Nicaragua
1
Portugal
1
Poland
1
Hong Kong
1
Slovenia
1
Germany
1
Argentina
1
South Africa
1
Belgium
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic